Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment

Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment

Glioblastomas (GBs) frequently display activation of the epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR). mTOR exists as part of two multiprotein complexes, mTOR complex 1 (mTORC1) and 2 (mTORC2). In GBs, mTORC1 inhibitors such as rapamycin have performed poorly in c...

Full description

Bibliographic Details
Main Authors: Dennis Heinzen, Iris Divé, Nadja I. Lorenz, Anna-Luisa Luger, Joachim P. Steinbach, Michael W. Ronellenfitsch
Format: Article
Language:English
Published: MDPI AG 2019-09-01
Series:International Journal of Molecular Sciences
Subjects:
glioblastoma
mTOR
mTOR inhibition
hypoxia
starvation
tumor microenvironment
Online Access:https://www.mdpi.com/1422-0067/20/18/4474

Internet

https://www.mdpi.com/1422-0067/20/18/4474

Similar Items